WuXi AppTec Completes Acquisition of HD Biosciences

We are pleased to announce WuXi has completed the acquisition of HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). Shanghai-based HD Biosciences' plate-based pharmacology and screening capability...
video

WuXi Global 2017 Forum Recap

More than 1,500 industry leaders gathered at the WuXi Global Forum 2017. The annual event, held in San Francisco during the J.P. Morgan Healthcare Conference on Jan. 10, promotes new thinking...

WuXi NextCODE Raises $75 Million in Series B Financing to Accelerate Growth of Global...

WuXi would like to congratulate WuXi NextCODE for raising $75 million in Series B financing, led by the company's current investors Temasek and Yunfeng Capital. WuXi NextCODE will focus the use of proceeds...

LabNetwork Integrates with Reaxys to Offer Seamless Experience from Chemistry Research to Purchase

We look forward to the new collaboration between LabNetwork, WuXi AppTec’s global chemistry ecommerce platform company, and Elsevier, a world-leading provider of scientific, technical and medical information products and services. Under the...

WuXi Biologics Receives Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC

We are pleased to announce that WuXi Biologics  has received the 2017 Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC, a leading consulting firm. WuXi Biologics has been recognized for its outstanding performance for...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Artificial Intelligence Poised to Transform the Drug Industry from Laboratory to...

Artificial intelligence (AI) –  which learns from computer algorithms how to unravel complex genomic data, such as gene expression patterns of disease – is...